title: Tranilast inhibits the proliferation of uterine leiomyoma cells in vitro through G1 arrest associated with the induction of p21(waf1) and p53.
abstract: Uterine leiomyoma is a mesenchymal tumor composed of smooth muscle cells with fibrous tissues and many mast cells. Tranilast is known to suppress fibrosis or to work as a mast cell stabilizer and is reported to inhibit proliferation of vascular smooth muscle cells. In this study, we examined the effects of tranilast on cultured human leiomyoma cells in vitro to evaluate whether this agent has the potential to inhibit the growth of uterine leiomyomas. Tranilast inhibited the proliferation of cultured leiomyoma cells in a dose-dependent manner without any cytotoxic effect or induction of apoptosis. In association with the inhibitory effect, tranilast induced the cyclin-dependent kinase (CDK) inhibitor p21(waf1) and tumor suppressor gene p53 and decreased CDK2 activity. These results suggest that tranilast arrests the proliferation of uterine leiomyoma cells at the G0/G1 phase, through the suppression of CDK2 activity via an induction of p21(waf1) and p53. Tranilast was concluded to be a potent agent to inhibit proliferative activity of uterine leiomyoma cells.
authors.affiliation: Department of Gynecology and Obstetrics, Kyoto University Graduate School of Medicine, Kyoto 606-8507, Japan.
authors.forename: Hiroaki
authors.initials: H
authors.lastname: Shime
authors.forename: Masatoshi
authors.initials: M
authors.lastname: Kariya
authors.forename: Ayaka
authors.initials: A
authors.lastname: Orii
authors.forename: Chika
authors.initials: C
authors.lastname: Momma
authors.forename: Takanobu
authors.initials: T
authors.lastname: Kanamori
authors.forename: Ken
authors.initials: K
authors.lastname: Fukuhara
authors.forename: Takashi
authors.initials: T
authors.lastname: Kusakari
authors.forename: Yuko
authors.initials: Y
authors.lastname: Tsuruta
authors.forename: Kenji
authors.initials: K
authors.lastname: Takakura
authors.forename: Toshio
authors.initials: T
authors.lastname: Nikaido
authors.forename: Shingo
authors.initials: S
authors.lastname: Fujii
mesh_terms: D015153:Blotting, Western; D042846:CDC2-CDC28 Kinases; D002453:Cell Cycle / Q000187:drug effects; D002455:Cell Division / Q000187:drug effects / Q000502:physiology; D051357:Cyclin-Dependent Kinase 2; D050759:Cyclin-Dependent Kinase Inhibitor p21; D018844:Cyclin-Dependent Kinases / Q000037:antagonists & inhibitors; D016213:Cyclins / Q000235:genetics; D005260:Female; D016193:G1 Phase; D005786:Gene Expression Regulation / Q000502:physiology*; D016158:Genes, p53; D006801:Humans; D007889:Leiomyoma / Q000473:pathology*; D009130:Muscle, Smooth / Q000166:cytology; D009215:Myometrium / Q000166:cytology; D017346:Protein Serine-Threonine Kinases / Q000037:antagonists & inhibitors; D014407:Tumor Cells, Cultured; D014594:Uterine Neoplasms / Q000473:pathology*; D062367:ortho-Aminobenzoates / Q000494:pharmacology*
chemical_list: C493956:CDKN1A protein, human; D050759:Cyclin-Dependent Kinase Inhibitor p21; D016213:Cyclins; D062367:ortho-Aminobenzoates; D017346:Protein Serine-Threonine Kinases; D042846:CDC2-CDC28 Kinases; C495894:CDK2 protein, human; D051357:Cyclin-Dependent Kinase 2; D018844:Cyclin-Dependent Kinases; C012293:tranilast